ArticleAnnals of hematology2026
EASIX score is predictive of early fatal complications in newly diagnosed acute myeloid leukemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early mortality in acute myeloid leukemia (AML) remains a clinical challenge, yet robust, simple predictors are lacking. This study evaluates the prognostic value of the Endothelial Activation and Stress Index (EASIX), calculated using LDH, creatinine, and platelets, for predicting early fatal complications in newly diagnosed (ND) AML. We conducted a retrospective single-center cohort study of 158 adult patients with ND AML treated with intensive induction chemotherapy. The EASIX score was calculated at diagnosis (day 1). The co-primary endpoints were ICU admission and death from any cause within 3 months. The median log2-EASIX was 2.10. Hish-risk patients (upper quartile, threshold 3.53) had significantly higher 3-month mortality (32.5% vs. 5.1%, p < 0.001) and ICU admission rates (50% vs. 19.6%, p < 0.001). In multivariate analysis, high EASIX was an independent predictor of 3-month mortality (OR 6.60; 95% CI 1.93–22.50) and ICU admission (OR 4.05, 95% CI 1.63–10.05). The EASIX score is a simple tool that predicts early adverse outcomes in ND AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.